167 related articles for article (PubMed ID: 31892961)
1. The Difference in Thyroid Stimulating Hormone Levels between Differentiated Carcinoma and Benign Enlargement.
Rianto BUD; Wibowo AS; Herdini C
Int Arch Otorhinolaryngol; 2020 Jan; 24(1):e73-e79. PubMed ID: 31892961
[No Abstract] [Full Text] [Related]
2. Naming difficulties after thyroid stimulating hormone suppression therapy in patients with differentiated thyroid carcinoma: a prospective cohort study.
Jin S; Yang YT; Bao W; Bai Y; Ai JW; Liu Y; Yong H
Endocrine; 2019 Aug; 65(2):327-337. PubMed ID: 31056722
[TBL] [Abstract][Full Text] [Related]
3. Higher preablative serum thyroid-stimulating hormone level predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma.
Lawal IO; Nyakale NE; Harry LM; Lengana T; Mokgoro NP; Vorster M; Sathekge MM
Nucl Med Commun; 2017 Mar; 38(3):222-227. PubMed ID: 28002173
[TBL] [Abstract][Full Text] [Related]
4. Endogenous thyrotropin and triiodothyronine concentrations in individuals with thyroid cancer.
Jonklaas J; Nsouli-Maktabi H; Soldin SJ
Thyroid; 2008 Sep; 18(9):943-52. PubMed ID: 18788918
[TBL] [Abstract][Full Text] [Related]
5. Management of coexisting thyrotropin/growth-hormone-secreting pituitary adenoma and papillary thyroid carcinoma: a therapeutic challenge.
Nguyen HD; Galitz MS; Mai VQ; Clyde PW; Glister BC; Shakir MK
Thyroid; 2010 Jan; 20(1):99-103. PubMed ID: 20067380
[TBL] [Abstract][Full Text] [Related]
6. Thyrotropin serum concentrations in patients with papillary thyroid microcancers.
Gerschpacher M; Göbl C; Anderwald C; Gessl A; Krebs M
Thyroid; 2010 Apr; 20(4):389-92. PubMed ID: 20210672
[TBL] [Abstract][Full Text] [Related]
7. Ectopic thyrotropin secreting pituitary adenoma concomitant with papillary thyroid carcinoma: Case report.
Yang J; Liu S; Yang Z; Shi YB
Medicine (Baltimore); 2017 Dec; 96(50):e8912. PubMed ID: 29390279
[TBL] [Abstract][Full Text] [Related]
8. A Prospective Study to Evaluate the Possible Role of Cholecalciferol Supplementation on Autoimmunity in Hashimoto's Thyroiditis.
Bhakat B; Pal J; Das S; Charaborty SK; SircarMedical NR; Kolkata ; RGKar ; NorthBengal ; Siliguri
J Assoc Physicians India; 2023 Jan; 71(1):1. PubMed ID: 37116030
[TBL] [Abstract][Full Text] [Related]
9. Effects of endocrine therapy on the prognosis of elderly patients after surgery for papillary thyroid carcinoma.
Xia Q; Dong S; Bian PD; Wang J; Li CJ
Eur Arch Otorhinolaryngol; 2016 Apr; 273(4):1037-43. PubMed ID: 25744048
[TBL] [Abstract][Full Text] [Related]
10. Levothyroxine Cessation After Thyroid Lobectomy for Papillary Thyroid Cancer Can Be Achieved at the Same Rate as that for Benign Tumors Regardless of the Duration of Thyroid-stimulating Hormone Suppression.
Na YM; Cho JS; Park MH
Anticancer Res; 2021 Nov; 41(11):5713-5721. PubMed ID: 34732444
[TBL] [Abstract][Full Text] [Related]
11. Thyroid hormone therapy in differentiated thyroid cancer.
Grani G; Ramundo V; Verrienti A; Sponziello M; Durante C
Endocrine; 2019 Oct; 66(1):43-50. PubMed ID: 31617165
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of risk factors for recurrence of differentiated thyroid carcinoma after surgical resection combined with iodine-131 and TSH suppression therapy].
Ye T; Lai S; Cao B; Xu B; Wang R
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2023 May; 37(5):370-374. PubMed ID: 37138400
[No Abstract] [Full Text] [Related]
13. Effects of thyroid-stimulating hormone suppression after thyroidectomy for thyroid cancer on bone mineral density in postmenopausal women: a systematic review and meta-analysis.
Kwak D; Ha J; Won Y; Kwon Y; Park S
BMJ Open; 2021 May; 11(5):e043007. PubMed ID: 33986046
[TBL] [Abstract][Full Text] [Related]
14. The magnitude of increased Levothyroxine dose during pregnancy in patients on thyroid-stimulating hormone (TSH) suppression treatment after total thyroidectomy for papillary carcinoma.
Minakata M; Ito M; Kishi T; Hada M; Masaki Y; Nakamura T; Kousaka K; Kasahara T; Kudo T; Nishihara E; Fukata S; Nishikawa M; Akamizu T; Miyauchi A
Endocr J; 2022 Feb; 69(2):165-172. PubMed ID: 34526424
[TBL] [Abstract][Full Text] [Related]
15. Development of Thyroid-Associated Ophthalmopathy in Patients Who Underwent Total Thyroidectomy.
Jang SY; Lee KH; Oh JR; Kim BY; Yoon JS
Yonsei Med J; 2015 Sep; 56(5):1389-94. PubMed ID: 26256985
[TBL] [Abstract][Full Text] [Related]
16. Thyroid stimulating hormone suppression and recurrence after thyroid lobectomy for papillary thyroid carcinoma.
Bae MR; Nam SH; Roh JL; Choi SH; Nam SY; Kim SY
Endocrine; 2022 Feb; 75(2):487-494. PubMed ID: 34689317
[TBL] [Abstract][Full Text] [Related]
17. Postoperative Thyroid-Stimulating Hormone Levels Did Not Affect Recurrence after Thyroid Lobectomy in Patients with Papillary Thyroid Cancer.
Lee MC; Kim MJ; Choi HS; Cho SW; Lee GH; Park YJ; Park DJ
Endocrinol Metab (Seoul); 2019 Jun; 34(2):150-157. PubMed ID: 31099202
[TBL] [Abstract][Full Text] [Related]
18. IS IT WORTH SUPPRESSING TSH IN LOW- AND INTERMEDIATE-RISK PAPILLARY THYROID CANCER PATIENTS BEFORE THE FIRST DISEASE ASSESSMENT?
Lamartina L; Montesano T; Falcone R; Biffoni M; Grani G; Maranghi M; Ciotti L; Giacomelli L; Ramundo V; Lomonaco C; Di Gioia CR; Piernatale L; Ronga G; Durante C
Endocr Pract; 2019 Feb; 25(2):165-169. PubMed ID: 30383494
[TBL] [Abstract][Full Text] [Related]
19. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
Chen CH; Chen JF; Yang BY; Liu RT; Tung SC; Chien WY; Lu YC; Kuo MC; Hsieh CJ; Wang PW
J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
[TBL] [Abstract][Full Text] [Related]
20. Biochemical Markers Reflecting Thyroid Function in Athyreotic Patients on Levothyroxine Monotherapy.
Ito M; Miyauchi A; Hisakado M; Yoshioka W; Ide A; Kudo T; Nishihara E; Kihara M; Ito Y; Kobayashi K; Miya A; Fukata S; Nishikawa M; Nakamura H; Amino N
Thyroid; 2017 Apr; 27(4):484-490. PubMed ID: 28056660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
